Head-to-head evidence
baricitinib vs Ruxolitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atopic Dermatitis
Shared mechanism: JAK1/2 · full Atopic Dermatitis pipeline
baricitinib · Olumiant
Marketed by Eli Lilly
NCT03334396 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial of 660 participants. The primary clinical endpoint was met for both 2 mg and 4 mg baricitinib: 11.4% and 16.8% achieved the specified IGA response versus 4.8% with placebo, with statistically significant comparisons.
Next expected readout: May 2030 · NCT07262983 (registry estimate)
Ruxolitinib
Marketed by Incyte
NCT03745638 · Phase 3 · completed
This was a randomized, quadruple-blinded, vehicle-controlled Phase 3 trial with 631 participants, comparing two doses of ruxolitinib cream against placebo. The primary endpoint was a clinician-assessed measure of disease severity (IGA treatment success at Week 8), and the comparison was met decisively: both ruxolitinib groups achieved significantly higher response rates than vehicle (50.0% and 53.8% vs 15.1%, each p<0.0001). The sample size was adequate, treatment assignment was concealed, and the hard clinical endpoint clearly favored active treatment.
Next expected readout: August 2027 · NCT07661979 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · Ruxolitinib's landscape